CN1309421C - 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合 - Google Patents

诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合 Download PDF

Info

Publication number
CN1309421C
CN1309421C CNB028077490A CN02807749A CN1309421C CN 1309421 C CN1309421 C CN 1309421C CN B028077490 A CNB028077490 A CN B028077490A CN 02807749 A CN02807749 A CN 02807749A CN 1309421 C CN1309421 C CN 1309421C
Authority
CN
China
Prior art keywords
cancer
rapamycin
tumor
purposes according
fluorouracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028077490A
Other languages
English (en)
Chinese (zh)
Other versions
CN1545419A (zh
Inventor
J·J·小吉邦斯
G·杜卡特
J·H·E·弗里施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1545419A publication Critical patent/CN1545419A/zh
Application granted granted Critical
Publication of CN1309421C publication Critical patent/CN1309421C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028077490A 2001-04-06 2002-04-05 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合 Expired - Fee Related CN1309421C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28238501P 2001-04-06 2001-04-06
US28238801P 2001-04-06 2001-04-06
US60/282,385 2001-04-06
US60/282,388 2001-04-06

Publications (2)

Publication Number Publication Date
CN1545419A CN1545419A (zh) 2004-11-10
CN1309421C true CN1309421C (zh) 2007-04-11

Family

ID=26961412

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028077490A Expired - Fee Related CN1309421C (zh) 2001-04-06 2002-04-05 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合

Country Status (21)

Country Link
EP (1) EP1385551B1 (enExample)
JP (1) JP2004525950A (enExample)
KR (1) KR100862178B1 (enExample)
CN (1) CN1309421C (enExample)
AT (1) ATE406892T1 (enExample)
AU (1) AU2007242958A1 (enExample)
BR (1) BR0208627A (enExample)
CA (1) CA2442849A1 (enExample)
DE (1) DE60228699D1 (enExample)
EA (1) EA010184B1 (enExample)
ES (1) ES2312568T3 (enExample)
HU (1) HUP0304093A3 (enExample)
IL (1) IL157898A0 (enExample)
MX (1) MXPA03009092A (enExample)
NO (1) NO20034433L (enExample)
NZ (1) NZ540047A (enExample)
PL (1) PL363991A1 (enExample)
PT (1) PT1385551E (enExample)
SG (1) SG152906A1 (enExample)
SI (1) SI1385551T1 (enExample)
WO (1) WO2002080975A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
LT2762140T (lt) * 2001-02-19 2017-06-26 Novartis Ag Solidinių smegenų navikų gydymas rapamicino dariniu
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
EP1732583A4 (en) * 2004-02-26 2009-08-12 Penn State Res Found COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS
WO2006027545A2 (en) * 2004-09-10 2006-03-16 Agency For Science, Technology And Research Method
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
BRPI0618042A2 (pt) * 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
CN102579467A (zh) * 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP2275103B1 (en) 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
CA2637069A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mtor inhibitor and antipolate compound
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
JP2009532503A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
US20090311249A1 (en) * 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
WO2008016633A2 (en) * 2006-08-02 2008-02-07 Ariad Gene Therapeutics, Inc. Combination therapy
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
JP5919593B2 (ja) * 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
KR20090108086A (ko) 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 췌장암 치료용 조성물
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
LT2481402T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
WO1999052514A2 (de) * 1998-04-14 1999-10-21 Eli Lilly And Company Pharmazeutische zusammensetzung und kombinationspräparate zur immunosuppressiven therapie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
JP4352115B2 (ja) * 1997-01-24 2009-10-28 クラヴィス・ファルマ・アーエスアー ゲムシタビン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
WO1999052514A2 (de) * 1998-04-14 1999-10-21 Eli Lilly And Company Pharmazeutische zusammensetzung und kombinationspräparate zur immunosuppressiven therapie

Also Published As

Publication number Publication date
PL363991A1 (en) 2004-11-29
EA200301091A1 (ru) 2004-02-26
NZ540047A (en) 2007-01-26
HK1060062A1 (en) 2004-07-30
CA2442849A1 (en) 2002-10-17
ES2312568T3 (es) 2009-03-01
NO20034433D0 (no) 2003-10-03
HUP0304093A2 (hu) 2004-04-28
DE60228699D1 (de) 2008-10-16
CN1545419A (zh) 2004-11-10
JP2004525950A (ja) 2004-08-26
KR100862178B1 (ko) 2008-10-09
NO20034433L (no) 2003-11-25
SI1385551T1 (sl) 2008-12-31
KR20040007491A (ko) 2004-01-24
AU2007242958A1 (en) 2008-01-10
EA010184B1 (ru) 2008-06-30
SG152906A1 (en) 2009-06-29
IL157898A0 (en) 2004-03-28
WO2002080975A1 (en) 2002-10-17
BR0208627A (pt) 2004-03-09
HUP0304093A3 (en) 2008-08-28
MXPA03009092A (es) 2004-02-12
ATE406892T1 (de) 2008-09-15
EP1385551A1 (en) 2004-02-04
PT1385551E (pt) 2008-11-03
EP1385551B1 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
CN1545419A (zh) 诸如雷帕霉素和吉西他滨或氟尿嘧淀的抗肿瘤联合
US20020183239A1 (en) Antineoplastic combinations
RU2632104C2 (ru) Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
US20030008923A1 (en) Antineoplastic combinations
US20070105887A1 (en) Antineoplastic combinations of temsirolimus and sunitinib malate
AU2008202690A1 (en) Antineoplastic combination
JP5709354B2 (ja) ｍＴＯＲ阻害剤投与によるがん患者の治療
US20020183240A1 (en) Antineoplastic combinations
CN113365610A (zh) 制备和递送比生群制剂的方法
AU2002259309A1 (en) Antineoplastic combinations
ZA200309816B (en) Antineoplastic combinations
TW201717926A (zh) 用於治療尤文氏家族腫瘤(ewing family tumors)的組成物及方法
AU2002257123A1 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
HK1060062B (en) Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070411

Termination date: 20100405